The potential pleiotropic effects of edoxaban in inflammation, atherosclerosis, and stroke have been experimentally tested in various models, with key findings suggesting that edoxaban is a promising target for inhibition of the PAR-2 pathway [199]. This evidence concerns the gene F2RL1 and atherosclerosis.